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Dear Sirs,  
 
Idiopathic basal ganglia calcifications (IBGC), also known as Fahr’s disease, are rare 
neurological diseases characterized by symmetric calcium deposits in the basal ganglia and other brain 
regions. Clinically, IBGC patients show high phenotypic heterogeneity, both in the neuradiological 
findings and in clinical manifestations. Recently, PDGFRB, PDGFB and SLC20A2 have been 
identified as causative genes for IBGC [2].  
We report the case of an Italian patient with IBGC associated with a novel mutation in the SLC20A2 
gene, who presented with episodic migraine. In September 2013, a 48-year-old woman presented to our 
outpatient clinic with a 29-years history of headache. The recurrent attacks were characterized by 
pulsating pain of moderate intensity in frontotemporal location, associated with severe nausea and 
photo/phonophobia, lasting up to 72 hours, with six-eight episodes a month. The reported symptoms 
fulfilled ICHD-III beta version criteria for episodic migraine without aura (code 1.1) [2]. The medical 
history of the patient was unremarkable. A positive family history for migraine (mother and maternal 
aunt) and psychosis (another maternal aunt) was reported. Neurological examination showed 
hyperreflexia and slightly neck rigidity, while no cerebellar signs were identified. A computed 
tomography scan showed severe calcifications at the bilateral globus pallidus, caudate nuclei, putamen, 
and dentate nuclei (Figure 1A). Laboratory tests were normal (including serum 25-hydroxyvitamin D 
and calcium concentrations) and excluded any parathyroid dysfunction. Neuropsychological screening 
showed a mild impairment in verbal fluency and mild attention deficit. The remaining 
neuropsycological tests had normal scores, also in those for visuospatial functions. STAIx-1 and 
STAIx-2 tests showed high level of anxiety. 
The patient received genetic counselling and on the basis of the neuroradiological findings with 
calcifications both in basal ganglia and cerebellum, SLC20A2 was sequenced. We analyzed the 
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candidate gene by direct genomic sequencing of the coding exons, performed on an ABI Prism 3130 
XL platform. We identified a novel frameshift mutation p.Val507Glufs*2 in the isoform 1 
(c.1520_1521delTG, exon 8, NM_006749) (Figure 1B,C). This genetic change was predicted to change 
an aminoacid and insert a stop codon, likely leading to a degradation of the mutated messanger RNA 
due to nonsense mediated decay [3]. No other relative was available for segregation analysis. 
SCL20A2 encodes the type III sodium dependent phosphate transporter 2, broadly expressed and with 
high levels in brain. SLC20A2 gene mutations have been reported in China, Brazil, Japan, and Spain  
[3-12], and all are predicted to give a loss-of-function, causing gene haploinsufficiency [3]. The 
mechanisms leading to calcifications remain to be elucidated, although a role for increased inorganic 
phosphate can be supposed [4]. 
The clinical manifestations in patients with IBGC range widely from neurological and/or psychiatric 
symptoms to asymptomatic status. Because migraine is a common disorder in general population 
(mainly in women), the coexistence of IBGC and migraine may be coincidental in our patient. On the 
other way, migraine has frequently been reported as symptom in a large series of IBGC patients with 
SLC20A2 mutations [13].  
The basal ganglia are involved in the integration of information between cortical and thalamic regions 
and in particular in domains involved in pain processing. Brain imaging studies of migraineurs have 
shown altered activation in the basal ganglia in comparison with controls [14]. In addition, migraine is 
reportedly more frequent in patients with other known basal ganglia disorders [15]. Our report might 
further support that basal ganglia may be involved in central pain processing and migraine 
pathophysiology.   
We suggest that migraine should be considered when evaluating patients with IBGC and their first-
degree relatives, in particular in young age, when other neurological symptoms are absent. The 
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identification of new genetic variants further enlarge the spectrum of mutations in SLC20A2, helping to 
better elucidate the worldwide distribution and the different clinical features.  
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Figure 1. A) Brain CT scans showing the locations of calcification in basal ganglia and cerebellum. 
B) Sequencing chromatogram showing the wild-type sequence and the heterozygous 
c.1520_1521delTG mutation in the SLC20A2 gene. The TG deleted nucleotides are boxed. C) Model of 
the PiT2 protein. Mutations described in the literature are reported (1-30): see legend for mutation 
types. The new mutation causes a Val 507 to Glu aminoacid change, and a frameshift with a stop codon 
at the next aminoacid. The C-terminal protein region lost in the p.Val507Glufs*2 mutant is highlighted. 
Mutations nomenclature was revised accordingly to Human Genome Variation society (HGV) 
(http://www.hgvs.org/mutnomen/; version September 13, 2013), and in [7, 8, 13, 14, 18, 26] is different 
from those reported in the original paper. 
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